These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 15217956)

  • 1. Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide.
    Thallinger C; Wolschek MF; Maierhofer H; Skvara H; Pehamberger H; Monia BP; Jansen B; Wacheck V; Selzer E
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4185-91. PubMed ID: 15217956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model.
    Thallinger C; Wolschek MF; Wacheck V; Maierhofer H; Günsberg P; Polterauer P; Pehamberger H; Monia BP; Selzer E; Wolff K; Jansen B
    J Invest Dermatol; 2003 Jun; 120(6):1081-6. PubMed ID: 12787138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy.
    Sieghart W; Losert D; Strommer S; Cejka D; Schmid K; Rasoul-Rockenschaub S; Bodingbauer M; Crevenna R; Monia BP; Peck-Radosavljevic M; Wacheck V
    J Hepatol; 2006 Jan; 44(1):151-7. PubMed ID: 16289418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bcl-2 antisense oligonucleotides are effective against systemic but not central nervous system disease in severe combined immunodeficient mice bearing human t(14;18) follicular lymphoma.
    Mohammad R; Abubakr Y; Dan M; Aboukameel A; Chow C; Mohamed A; Hamdy N; Al-Katib A
    Clin Cancer Res; 2002 Apr; 8(4):1277-83. PubMed ID: 11948143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mcl-1 blocks radiation-induced apoptosis and inhibits clonogenic cell death.
    Skvara H; Thallinger C; Wacheck V; Monia BP; Pehamberger H; Jansen B; Selzer E
    Anticancer Res; 2005; 25(4):2697-703. PubMed ID: 16080514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1.
    Gojo I; Zhang B; Fenton RG
    Clin Cancer Res; 2002 Nov; 8(11):3527-38. PubMed ID: 12429644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
    Loomis R; Carbone R; Reiss M; Lacy J
    Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide.
    Klasa RJ; Bally MB; Ng R; Goldie JH; Gascoyne RD; Wong FM
    Clin Cancer Res; 2000 Jun; 6(6):2492-500. PubMed ID: 10873104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer.
    Hu Y; Bebb G; Tan S; Ng R; Yan H; Sartor JR; Mayer LD; Bally MB
    Clin Cancer Res; 2004 Nov; 10(22):7662-70. PubMed ID: 15569999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis.
    Tortora G; Caputo R; Damiano V; Bianco R; Fontanini G; Cuccato S; De Placido S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2001 Aug; 7(8):2537-44. PubMed ID: 11489837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bcl-2 antisense oligonucleotides chemosensitize human gastric cancer in a SCID mouse xenotransplantation model.
    Wacheck V; Heere-Ress E; Halaschek-Wiener J; Lucas T; Meyer H; Eichler HG; Jansen B
    J Mol Med (Berl); 2001 Oct; 79(10):587-93. PubMed ID: 11692156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic antitumoral activity and induction of apoptosis by novel pan Bcl-2 proteins inhibitor apogossypolone with adriamycin in human hepatocellular carcinoma.
    Mi JX; Wang GF; Wang HB; Sun XQ; Ni XY; Zhang XW; Tang JM; Yang DJ
    Acta Pharmacol Sin; 2008 Dec; 29(12):1467-77. PubMed ID: 19026166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor regression by combination antisense therapy against Plk1 and Bcl-2.
    Elez R; Piiper A; Kronenberger B; Kock M; Brendel M; Hermann E; Pliquett U; Neumann E; Zeuzem S
    Oncogene; 2003 Jan; 22(1):69-80. PubMed ID: 12527909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing's sarcoma.
    Mateo-Lozano S; Gokhale PC; Soldatenkov VA; Dritschilo A; Tirado OM; Notario V
    Clin Cancer Res; 2006 Nov; 12(22):6781-90. PubMed ID: 17121899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CpG immunomer DNA enhances antisense protein kinase A RIalpha inhibition of multidrug-resistant colon carcinoma growth in nude mice: molecular basis for combinatorial therapy.
    Nesterova MV; Johnson NR; Stewart T; Abrams S; Cho-Chung YS
    Clin Cancer Res; 2005 Aug; 11(16):5950-5. PubMed ID: 16115938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence.
    Zupi G; Scarsella M; Semple SC; Mottolese M; Natali PG; Leonetti C
    Clin Cancer Res; 2005 Mar; 11(5):1990-8. PubMed ID: 15756025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
    Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
    Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.
    Mohammad RM; Goustin AS; Aboukameel A; Chen B; Banerjee S; Wang G; Nikolovska-Coleska Z; Wang S; Al-Katib A
    Clin Cancer Res; 2007 Apr; 13(7):2226-35. PubMed ID: 17404107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity.
    Hussain SR; Cheney CM; Johnson AJ; Lin TS; Grever MR; Caligiuri MA; Lucas DM; Byrd JC
    Clin Cancer Res; 2007 Apr; 13(7):2144-50. PubMed ID: 17404098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
    Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M
    Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.